Villani P, Cocchi L, Giacchino R, Seminari E, Regazzi M B, Maserati R
Dipartimento di Farmacologia, IRCCS Policlinico S. Matteo, Università degli Studi di Pavia.
Clin Ter. 1996 Jun;147(6):279-93.
The number of subjects with HIV infection or full-blown Acquired Immunodeficiency Syndrome (AIDS) is increasing throughout the world and the range of related opportunistic conditions (infections, neoplasms or degenerative disorders) is also increasing. Consequently, AIDS patients are likely to be prescribed a great number of different drugs. HIV infection is a progressive phenomenon, characterized by inevitable and often irreversible changes which may influence drug disposition, enhancing the risk of toxic adverse effects and drug interactions. One of the stages for the development of new agents and the establishment of an effective therapy is to conduct pharmacokinetic studies. Even though such studies are difficult to realize in AIDS subjects, the knowledge of altered pharmacokinetics of a drug in disease states offers an unique approach for improving and perhaps optimizing the therapeutic management. The purpose of this article is to review our current understanding of how HIV infection influences the various processes of drug disposition (i.e. absorption, distribution, metabolism and excretion).
全球感染人类免疫缺陷病毒（HIV）或罹患全面性获得性免疫缺陷综合征（AIDS）的患者数量正在增加，相关机会性疾病（感染、肿瘤或退行性疾病）的范围也在扩大。因此，AIDS患者可能会被开具大量不同的药物。HIV感染是一种进行性疾病，其特征是不可避免且往往不可逆转的变化，这些变化可能会影响药物的处置，增加毒性不良反应和药物相互作用的风险。开发新药物和建立有效治疗方法的其中一个阶段是进行药代动力学研究。尽管此类研究在AIDS患者中难以实现，但了解疾病状态下药物药代动力学的改变为改善甚至优化治疗管理提供了独特的方法。本文的目的是综述我们目前对HIV感染如何影响药物处置的各个过程（即吸收、分布、代谢和排泄）的理解。
